Recent News
Read ArticleDr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?
Interferons and Lupus Subsets
In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights as to the relationship between interferons and lupus, which affects up to 1.5 million Americans.
https://t.co/53locWebEb https://t.co/q1hkSwHYKM
Dr. John Cush @RheumNow ( View Tweet)
Risk Factors for Hydroxychloroquine Retinopathy
A long-term hydroxychloroquine users study found that 2.7% developed retinopathy, and identified risk factors as increasing age, female sex, chronic kidney disease stage 3+ and tamoxifen use.
https://t.co/iC7eh0XLzE https://t.co/gDaWi4kt1h
Dr. John Cush @RheumNow ( View Tweet)
Metanalysis of 26 reports and 195 juvenile Dermatomyositis pts (age 4.9 yrs) treated w/ JAK inhib (tofa, rux, & bari); Good improvement in 90%, 69% & 93%, respectively. JAK indication refractory skin dz (35%) or muscle involvement (29%). TIME FOR RCTs!! https://t.co/Vtm2n9BWV1 https://t.co/1bXZokW1AO
Links:
Dr. John Cush @RheumNow ( View Tweet)
Review article of Interstitial Lung Dz Assoc w/ Systemic Sclerosis. SSc-ILD prevalence ranges 25-95%; ILD is a main cause of morbidity and mortality, contributing to 35% of deaths https://t.co/8mMFbDu4gi https://t.co/nQ4GfNcMWt
Links:
Dr. John Cush @RheumNow ( View Tweet)
Alot of murky "research" on Platelet-rich plasma (PRP). This RCT of120 pts having anterior cruciate ligament reconstruction (half randomized to PRP) shows no PRP benefit, no significant improvement of knee symptoms & function post ACLR https://t.co/AwkCAq1QFb https://t.co/YP0hJd7soc
Dr. John Cush @RheumNow ( View Tweet)
Retrospective cohort study compared 5825 #AS pts vs 28,356 matched controls; showed an increased risk of pulmonary embolism w/ AS; not present pre-Dx ((0.4% vs 0.2%), but incr post-AS Dx (PE IR 11.6 vs 6.8/10KPY: adj HR 1.70;; p<0.001) https://t.co/wSkAMozvnL https://t.co/5Q470QkAxe
Dr. John Cush @RheumNow ( View Tweet)
K Kuhn et al: Altered tryptophan catabolism by microbiome may contribute to inflammatory arthritis. Tryptophan increases indole leading to ncreases in serum IL-6, TNF, and IL-1β; splenic RORγt+CD4+ T cells, & IL-23 and IL-17 production https://t.co/i9le12QZm2 https://t.co/akeXxWnQ9o
Dr. John Cush @RheumNow ( View Tweet)
Substitute Measures of Inflammation (many dervied from the CBC)
https://t.co/b2AuVERJQn https://t.co/QXZ8GthsMW
Dr. John Cush @RheumNow ( View Tweet)
My Cancelled Lecture Slides
Listen to last week's podcast for more context!
https://t.co/C3bm2psfxZ https://t.co/sjIgDiVKtK
Dr. John Cush @RheumNow ( View Tweet)
Infectious Mortality in ARD
Infectious conditions are a significant cause of mortality in ARD. Among patients hospitalized with an infection, we compared in-hospital and long-term (3-year) mortality between those with and without ARD.
https://t.co/p4n5Los89F https://t.co/vUBLC9TDDG
Dr. John Cush @RheumNow ( View Tweet)
Save the date! We’ll be covering #EULAR24! https://t.co/HGjP2SFyOp
Dr. John Cush @RheumNow ( View Tweet)
Small-molecule Drugs to Treat Systemic Lupus Erythematosus
A metanalysis of randomized controlled trials (RCTs) on treatments of systemic lupus erythematosus (SLE), confirm the efficacy of several targeted small-molecule drugs.
https://t.co/ZYPZcfKrBD https://t.co/ZGYFNVgN0s
Dr. John Cush @RheumNow ( View Tweet)
Legal (Not So) Merry-Go-Round of Alendronate Atypical Fractures
Dr. Gregory Curfman, MD (Executive editor of JAMA) writes on the chronological legal progress of a lawsuit stemming from rare instances of atypical femoral fractures associated with bisphosphonate (alendronate) use. While alendronate was FDA approved in 1995 for the prevention and treatment of osteoporosis, and legal action was initiated in 2011, there is still no legal resolution to this issue.
Read Article
Antacids can Diminish Bone Density
EurekAlert!
Proton pump inhibitors (PPIs), a specific class of antacid drugs, are among the most widely used medications of all. They are frequently prescribed to many groups of patients, including those with rheumatism. PPIs are used to prevent the stomach problems that can arise from taking certain anti-inflammatory drugs.
Read Article
A unique study in military medicine of 1.5 million ED visits reveals the dynamics of high-rank and high-power patients and doctors, and the care they get/provide
https://t.co/hbsUt1s9YR
@ScienceMagazine @sdschwab @vini_singh_ https://t.co/RIjq4awgeR
Links:
Eric Topol @EricTopol ( View Tweet)
Interferons and Lupus Subsets
In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights as to the relationship between interferons and lupus, which affects up to 1.5 million Americans.
https://t.co/eWnNqVUpK9 https://t.co/yNp4GYHYKu
Dr. John Cush @RheumNow ( View Tweet)
Risk Factors for Hydroxychloroquine Retinopathy
A long-term hydroxychloroquine users study found that 2.7% developed retinopathy, and identified risk factors as increasing age, female sex, chronic kidney disease stage 3+ and tamoxifen use.
https://t.co/3HWWoCMXfI https://t.co/TuYgzRJEzR
Dr. John Cush @RheumNow ( View Tweet)
Single center EHR study of 5 064 pts w/ pre-diabetes compared those starting metformin (1154) vs 13 877 non-users w/ ~4 yrs F/U. Incidence of future gout was lower w/ metformin use (7.1 vs 9.5/1000PYs; HR 0.68); with no change in SUA or CRP https://t.co/CXdcEdWXhW https://t.co/j0ktehf9Sm
Dr. John Cush @RheumNow ( View Tweet)
2023 Top 3 paper from JAMA Derm - 122 plaque psoriasis pts (mild-mod w/ PASI=3.1) & low vit D levels (~14.9), Rx w/ PBO vs vit D 20 000 IU/wk x 4 mos during winter; no signif vit D Rx benefit for PASI, MD global, DLQI or 25-OH levels(< than expected) https://t.co/8W5abvydY6 https://t.co/rKJjkiHwC6
Dr. John Cush @RheumNow ( View Tweet)
My Cancelled Lecture (5.11.2024)
In lieu of this weeks podcast, Dr. Jack Cush records his "Life Lessons (that keep changing) in Rheumatology Lecture. A lecture recently cancelled because some of this content was objectionable? (I dont think so!)
https://t.co/8iObw8cE5S https://t.co/k06P4mMwmD
Dr. John Cush @RheumNow ( View Tweet)
From the blog
One of the first words I was taught by my parents was “chào”. In Vietnamese, you say chào and bow when you greet someone or when you leave as a sign of respect.
In my first blog about self-discovery, I detailed the burnout and why I left clinical practice. In this second blog of the trilogy, I wanted to share encounters with patients as I told them goodbye. While I received great advice when I started practice, no one ever talks about how hard it is to leave.
Read Post
Podcasts
Don't You Know Who I Am (5.17.2024)-
My Cancelled Lecture (5.11.2024)
Roadblocks to reaching remission in lupus Sponsored by GSK US Medical Affairs-
Featured BSR Abstracts (5.3.2024)
Therapeutic Updates
Approaches for slowing organ damage progression in lupus
Sponsored by GSK US Medical Affairs
Watch our videos featuring global rheumatology experts to learn about recent advances towards slowing organ damage progression in lupus. Discover how you can implement disease modification and remission treatment goals, alongside corticosteroid tapering and the earlier introduction of biologics, to help improve patient outcomes.
Read Post
